Molnar Ottó, Mihuțiu Simona, Ilea Codrin D, Vesa Alexandra, Straciuc Oreste M, Németh Noémi, Lazăr Liviu
Doctoral Studies Department, Biomedical Science, University of Oradea, Oradea, ROU.
Department of Medicine-Psycho-Neuroscience and Recovery, University of Oradea, Oradea, ROU.
Cureus. 2024 Jul 29;16(7):e65629. doi: 10.7759/cureus.65629. eCollection 2024 Jul.
Cervical cancer is the fourth most dangerous malignancy worldwide in women and is diagnosed at the advanced stages in most cases. Oncological and surgical modalities when precisely employed together can prove to be helpful for determining the proper diagnosis and treatment strategies. Neoadjuvant chemotherapy (NACT) has been found to have a role in reducing tumor size and has evolved as a treatment regimen for locally advanced cervical cancer (LACC). The present study aimed to analyze the treatment strategies either with neoadjuvant platinum-based chemotherapy (NACT) administration or not and pathological responses in patients with LACC.
We reviewed 100 patients of LACC from October 2018 to December 2022 at Bihor County Emergency Clinical Hospital. About 43 patients underwent radiation therapy in addition to NACT administration (NACT+/other) and 57 underwent other treatment regimens without neoadjuvant treatment (NACT-/ other). Various demographic parameters, FIGO staging, histological status, surgical interventions, and survival rate (local disease-free survival (LDFS) and disease-free survival (DFS)) were accessed in both groups. Statistical analysis was performed to analyze the significance of various parameters studied.
The mean age range of the studied sample was 57.05 ± 12.51 in NACT+/other and 60.4±12.32 in NACT-/other. Among 100 patients, 90 cases of squamous carcinoma, eight of adenocarcinoma, and two cases of adenosquamous carcinoma were analyzed and treated. At stage IIIC1, 11 patients were accessed while 15 patients were at clinical stage IIIC2, and among these, 25.58% received neoadjuvant oncological treatment and very limited mediastinal disease. DFS rates are greater in the patients who have undergone surgery in the NACT+/other group, while in the LDFS, there is better survival in the case of surgery without any NACT treatment (NACT-/other).
The effect of NACT can be suggested as another important treatment strategy and result in a good response in terms of DFS and LDFS in patients with LACC. This approach aims to reduce tumor size preoperatively, facilitating surgical removal and potentially improving patient outcomes compared to other treatment modalities. Thus, it can be concluded that NACT may be considered an important strategy to be opted for the treatment of LACC.
宫颈癌是全球女性中第四大危险的恶性肿瘤,大多数病例在晚期才被诊断出来。精确联合使用肿瘤学和手术方法有助于确定正确的诊断和治疗策略。新辅助化疗(NACT)已被发现可缩小肿瘤大小,并已发展成为局部晚期宫颈癌(LACC)的一种治疗方案。本研究旨在分析接受或未接受基于铂类的新辅助化疗(NACT)的治疗策略以及LACC患者的病理反应。
我们回顾了2018年10月至2022年12月在比霍尔县急诊临床医院的100例LACC患者。约43例患者除接受NACT外还接受了放射治疗(NACT +/其他),57例患者接受了其他无新辅助治疗的治疗方案(NACT -/其他)。在两组中均获取了各种人口统计学参数、国际妇产科联盟(FIGO)分期、组织学状态、手术干预以及生存率(局部无病生存率(LDFS)和无病生存率(DFS))。进行统计分析以分析所研究的各种参数的意义。
在NACT +/其他组中,研究样本的平均年龄范围为57.05±12.51岁,在NACT -/其他组中为60.4±12.32岁。在100例患者中,分析并治疗了90例鳞状细胞癌、8例腺癌和2例腺鳞癌。在IIIC1期,有11例患者,在临床IIIC2期有15例患者,其中25.58%接受了新辅助肿瘤治疗且纵隔疾病非常有限。在NACT +/其他组中接受手术的患者DFS率更高,而在LDFS方面,未接受任何NACT治疗(NACT -/其他)的手术患者生存率更高。
NACT的效果可被视为另一种重要的治疗策略,并且在LACC患者的DFS和LDFS方面能产生良好反应。这种方法旨在术前缩小肿瘤大小,便于手术切除,并与其他治疗方式相比可能改善患者预后。因此,可以得出结论,NACT可被视为治疗LACC的一种重要策略。